Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A cerebrohepatopathy and a rare and severe form of mitochondrial DNA (mtDNA) depletion syndrome characterized by the triad of progressive developmental regression, intractable seizures, and hepatic failure.
Features include always present findings: Ataxia, Cerebral visual impairment, and Brain shrinkage (cerebral atrophy); and common findings: Encephalopathy, Bile duct proliferation, Tracheomalacia, and Acute hepatic failure and others. 46 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 15 | Encephalopathy, Ataxia, Global developmental delay |
Digestive system | 9 | Acute hepatic failure, Jaundice, Ascites |
Muscles | 4 | Low muscle tone (hypotonia), Generalized hypotonia, Shrinkage of the cerebellum (cerebellar atrophy) |
Lab test results | 3 | Increased circulating lactate concentration, Elevated circulating hepatic transaminase concentration, Increased CSF protein concentration |
Bones and joints | 2 | Weak and brittle bones (osteoporosis), Sideways curvature of the spine (scoliosis) |
Lungs and breathing | 1 | Hypoventilation |
Growth and development | 1 | Failure to thrive |
Eyes | 1 | Cerebral visual impairment |
POLG-related disorders comprise a continuum of broad and overlapping phenotypes that range from fatal neonatal-onset disease to mild late-onset disease with myopathy and progressive external ophthalmoplegia (PEO). Although some affected individuals present with one of the clinical entities caused by POLG pathogenic variants, many have some, but not all, of the features of one or more of the recognized phenotypes. Although clinical phenotypes in affected individuals from the same family are often similar, ages of onset, specific features, and rate of progression may differ. POLG-related disorders can therefore be considered an overlapping spectrum of disease presenting from early childhood to late adulthood. The age of onset broadly correlates with the clinical phenotype . summarizes the clinical findings in POLG-related disorders. Table 2. Clinical Findings in POLG-Related Disorders
System | Manifestation | % of Persons w/Manifestation |
|---|---|---|
Neurologic | Epilepsy (incl myoclonic, focal motor generalized seizures, status epilepticus, epilepsia partialis continua) | ~70% Tone abnormalities (most commonly hypotonia) |
Gastrointestinal | Liver issues (most notably liver failure that is either spontaneous or precipitated by valproic acid or sodium divalproate in children) | ~64% Gastrointestinal dysmotility (incl vomiting, diarrhea, feeding difficulties) |
Ophthalmologic | Cataracts | ~7% Ptosis external ophthalmoplegia |
Audiologic | Sensorineural hearing loss | ~11% Neuromuscular/ |
myopathy | Proximal or distal myopathy | ~70% Exercise intolerance |
Endocrine | Primary ovarian failure ovarian dysgenesis | Rare Primary testicular failure |
Renal | Renal tubular acidosis, kidney failure, kidney stones | ~11% (MCHS) |
Respiratory | Ventilatory Weakness (muscle, nerve, central respiratory drive) | ~12% Based on , , , , and MCHS = childhood myocerebrohepatopathy spectrum 1. |
Source: GeneReviews — "POLG-Related Disorders"
POLG function has not been fully characterized.
Mitochondrial DNA depletion syndrome 4a is associated with mutations in the POLG gene on chromosome 15.
No clinically relevant genotype-phenotype correlations have been identified.
Source: GeneReviews — "POLG-Related Disorders"
POLG-related disorders comprise a continuum of overlapping phenotypes. A POLG-related disorder should be suspected in individuals with combinations of the following clinical features and laboratory and neuroimaging findings. Clinical features. Clinical features form a continuum but vary in their age of onset. Apart from progressive external ophthalmoplegia (PEO)/ ptosis, other features could present at any time from infancy to adulthood. The most common clinical features by age of onset are:
• Prior to age 12 years (early-onset disease):
Liver involvement (See .)
Feeding difficulties
Seizures
Hypotonia and muscle weakness that can evolve into corticospinal tract dysfunction (spasticity and dystonia)
• Between age 12 and 40 years (juvenile/adult-onset disease):
Source: GeneReviews — "POLG-Related Disorders"
Table 4. Genes of Interest in the Differential Diagnosis of POLG-Related Disorders
Gene(s)1/Genetic Mechanism | Disorder | MOI | Comment |
|---|---|---|---|
ALDH7A1 | Pyridoxine-dependent epilepsy – ALDH7A1 (pyridoxine-dependent epilepsy) | AR | Neonatal-onset progressive encephalopathy w/refractory seizures; Targeted therapy: seizures are not well controlled w/ASMs but respond to large daily supplements of pyridoxine (vitamin B6). AMT |
GLDC | Nonketotic hyperglycinemia (NKH) |
Genetic testing for POLG is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for mitochondrial DNA depletion syndrome 4a has been reported in the published literature.
No approved treatments are currently available for mitochondrial DNA depletion syndrome 4a. The disease remains an area of unmet medical need.
No clinical practice guidelines for POLG-related disorders have been published, although consensus statement guidelines for primary mitochondrial diseases are available .
To establish the extent of disease and needs in an individual diagnosed with POLG-related disorder, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Evaluation should always include measures of functional neurologic status.
Table 5.
POLG-Related Disorders: Recommended Evaluations Following Initial Diagnosis
System | Evaluation | Comment
| Neurologic eval | • To incl brain MRI1
Consider EEG video EEG if seizures are a concern.
| Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:
Gross motor fine motor skills
Mobility, ADL, need for adaptive devices
Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education, need for speech therapy
Neurobehavioral/
| Neuropsychiatric eval | For persons age 12 mos: screening for concerns incl sleep disturbances, ADHD, anxiety, /or findings suggestive of ASD. Formal neuropsychological eval can be considered for those w/any concerns identified on screening.
Depression screen | Assess for mood disturbances.
| Orthopedics/ physical medicine rehab/ PT OT eval | To inc...
Source: GeneReviews — "POLG-Related Disorders"
Valproic acid (Depakene®) and sodium divalproate (divalproex) (Depakote®) should be avoided because of the risk of precipitating and/or accelerating liver disease . As with some other mitochondrial diseases, physical stressors such as infection, fever, dehydration, and anorexia can result in a sudden deterioration and should be avoided if possible.
Source: GeneReviews — "POLG-Related Disorders"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "POLG-Related Disorders"
View trials for mitochondrial DNA depletion syndrome 4a
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, evaluations by a multidisciplinary team including neurologist, biochemical geneticist, hepatologist or gastroenterologist, physiatrist, psychiatrist, neuropsychologist and/or psychologist, ophthalmologist, and pulmonologist are recommended. No standard-of-care guidelines regarding the recommended frequency of evaluations exist; surveillance should be guided by clinical features, and the schedule should be modified if the clinical course is stable. For those with the most severe phenotypes, the recommendations in can be considered.
Table 7.
POLG-related disorders: Recommended Surveillance
System/Concern | Evaluation | Frequency
| • Monitor those w/seizures as clinically indicated.
Assess for new manifestations such as seizures, changes in tone, movement disorders.
EEG video EEG monitoring (e.g., for suspicion of subclinical status epilepticus or EPC, to determine if events are seizures or non-epileptic movements)
| At each visit
| Monitor developmental progress educational needs.
Neurobehavioral/
| Assessment for anxiety, ADHD, ASD, aggression, depression
| Physical medicine, OT/PT assessment of mobility, self-help skills
| • Measurement of growth parameters
Eval of nutritional status safety of oral intake
| • Complete blood count
Source: GeneReviews — "POLG-Related Disorders"
Phenotype severity distribution: 3 always present features, 23 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for mitochondrial DNA depletion syndrome 4a.
27 publications have been identified in PubMed for mitochondrial DNA depletion syndrome 4a. Research spans Basic Science / Preclinical (37%), Review / Meta-Analysis (26%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 10 | 37% |
Research summaries | 7 | 26% |
Patient case studies | 5 | 19% |
Disease patterns and progression | 3 | 11% |
Testing and diagnosis research | 1 | 4% |
Clinical study results | 1 | 4% |
Alfonso-Cedeño DF (2026). [PMID: 41619449](https://pubmed.ncbi.nlm.nih.gov/41619449/). *J Neuroimmunol*. [Review / Meta-Analysis]
Baltaci MA (2026). [PMID: 41693020](https://pubmed.ncbi.nlm.nih.gov/41693020/). *Rheumatology (Oxford)*. [Diagnostic / Biomarker]
Percy C (2026). [PMID: 41099389](https://pubmed.ncbi.nlm.nih.gov/41099389/). *JMIR Form Res*. [Case Report / Case Series]
Lanzante M (2026). [PMID: 42102330](https://pubmed.ncbi.nlm.nih.gov/42102330/). *Neurology*. [Case Report / Case Series]
Motta S (2026). [PMID: 41992872](https://pubmed.ncbi.nlm.nih.gov/41992872/). *J Chem Inf Model*. [Basic Science / Preclinical]
Dempegioti CA (2026). [PMID: 41207107](https://pubmed.ncbi.nlm.nih.gov/41207107/). *J Neuroimmunol*. [Basic Science / Preclinical]
Etemadifar M (2025). [PMID: 39842344](https://pubmed.ncbi.nlm.nih.gov/39842344/). *J Neuroimmunol*. [Review / Meta-Analysis]
Uygun A (2025). [PMID: 40586951](https://pubmed.ncbi.nlm.nih.gov/40586951/). *Int J Hematol*. [Epidemiology / Natural History]
Kanbay M (2025). [PMID: 39781479](https://pubmed.ncbi.nlm.nih.gov/39781479/). *Clin Kidney J*. [Review / Meta-Analysis]
Bao S (2025). [PMID: 40556660](https://pubmed.ncbi.nlm.nih.gov/40556660/). *Front Cardiovasc Med*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 9:33 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AR |
Epilepsia partialis continua has been described in some affected persons.2 |
ATP7A | Menkes disease (See ATP7A-Related Copper Transport Disorders.) | XL | Neonatal-onset progressive encephalopathy w/refractory seizures; Usually present earlier in infancy than AHS |
BCS1L | BCS1L-related disorders (incl GRACILE syndrome [OMIM 603358], Bjrnstad syndrome [OMIM 262000], GRACILE syndrome-Bjrnstad syndrome overlap phenotype] | AR | The clinical scenario of a hepatoencephalopathy may appear similar to AHS at a single point in time, but mtDNA depletion is not part of the pathology described in those w/BCS1L pathogenic variants. BTD |
Biotinidase deficiency | AR | Neonatal-onset progressive encephalopathy w/refractory seizures; Targeted therapy: Oral biotin. Adherence to biotin therapy can prevent development of disease also improves symptoms in symptomatic persons. | — |
CACNA1A | CACNA1A-related early infantile epileptic encephalopathy (OMIM 617106) | AD | Severe infantile epileptic disorder that appears progressive at onset but usually plateaus into developmental arrest/delay |
CACNB4 | Idiopathic generalized epilepsy myoclonic epilepsy (OMIM 607682) episodic ataxia type 5 (OMIM 613855) | AD | Early-onset epileptic disorder that is often assoc w/myoclonic, generalized tonic-clonic, or absence seizures w/photosensitivity reported in some persons3 CERS1 CSTB EPM2A GOSR2 KCNC1 KCTD7 LMNB2 NHLRC1 PRDM8 PRICKLE1 SCARB2 SEMA6B |
SLC7A6OS | Myoclonic epilepsy (OMIM PS254800) | ARAD | Can cause dementia or pseudodementia because of unrelenting seizures anticonvulsant side effects CLN5 CLN6 CLN8 PPT1 |
TPP1 | CLN1 disease CLN2 disease (neuronal ceroid lipofuscinoses [NCLs]) | AR | Phenotypes incl in NCLs that overlap w/AHS are CLN1 disease, classic infantile (previously classic infantile NCL, INCL, Santavuori-Haltia) CLN2 disease, classic late infantile (previously late-infantile NCL, LINCL, Jansky-Bielschowsky disease) |
COQ8A | COQ8A-related primary coenzyme Q10 (CoQ10) deficiency | AR | Epilepsia partialis continua has been described in some affected persons.4; Targeted therapy: Persons w/primary CoQ10 deficiency may respond well to high-dose oral CoQ10 supplementation. |
CTSA | Galactosialidosis (OMIM 256540) | AR | During infancy early childhood, storage diseases can be assoc w/progressive encephalopathy w/primary involvement of cortical gray matter refra... |
Source: GeneReviews — "POLG-Related Disorders"